Stay updated on Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page.

Latest updates to the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page
- Check5 days agoChange DetectedRevision notes indicate an update to v3.4.3 on 2026-03-10 and 2026-03-11, replacing the previous v3.4.2.SummaryDifference0.2%

- Check12 days agoChange DetectedStudy record dates and last-updated timestamps were updated on 2026-03-03, 2026-02-11, and 2025-12 to reflect recent maintenance.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now shows Revision: v3.4.2 and the prior funding notice and Revision: v3.4.1 have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedAn administrative funding-status notice was added and the page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedAdded a Show glossary option on the page and introduced QC metadata fields Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0. Removed the previous QC metadata items Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4.SummaryDifference0.2%

- Check62 days agoChange DetectedA minor revision label was updated from Revision: v3.3.3 to Revision: v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page.